Computational Antibody Papers

Filter by tags
All
Filter by published year
All
TitleKey points
    • Novel structural co-folding method that rivals AF3 architectures whilst being completely open sourced.
    • OpenDDE replaces direct coordinate regression with atomic latent reasoning over granular structural tokens and scales the standard Pairformer hidden dimension from 128 to 384, expanding parameter capacity.
    • The model implements a differentiable shape-complementarity objective to physically fit interfaces and naturally unifies structure prediction and de novo design inside a single conditional diffusion framework via masking.
    • The model uses a 4-stage precision-breadth-precision data distribution to master geometry , consuming ~414k GPU-hours handled efficiently via Fold-CP context parallelism.
    • The model sets state-of-the-art antibody-antigen success rates (e.g., 70.0% on FoldBench-AB and 66.4% on 2026ARK-AB) , easily outperforming Protenix-v1 (beating/equalling AF3!), and climbs to nearly 90% oracle accuracy when scaled with test-time seeds.
    • Developability characterization of multispecific antibodies, for the purposes of training machine learning models
    • To map out developer behavior, the researchers used advanced diversity-sampling algorithms to select 160 unique bispecific combinations from 65 parental antibodies, capturing a vast spectrum of biophysical profiles.
    • Developability traits don’t transfer uniformly from parent to child; while hydrophobicity and charge are highly predictable, critical flaws like self-association often emerge unexpectedly as "outliers" when the two arms interact.
    • The study revealed that thermostability is strictly format-driven, meaning it cannot be reliably predicted from parental data and must be measured directly on the final multi-specific construct.
  • 2026-07-13

    Modelling antibody structures at the speed of language

    • developability
    • structure prediction
    • Very fast antibody modeling, FlashABB, with applications to developability screening.
    • FlashABB accurately performs sota antibody antibody structure prediction in just 5 ms, making it faster than protein language models can even generate sequence embeddings, by completely discarding traditional pair representations in favor of an inner-product-based, linear-memory "Flashpoint Attention" (FPA) algorithm.
    • Featuring roughly 7.2 million parameters trained on 8,395 SAbDab structures, the model is strictly forced to run on float32 precision to avoid the catastrophic numerical cancellation errors that heavily degrade 16-bit float implementations during distance calculations.
    • Eliminating the structural compute bottleneck allows developers to scale downstream analysis to millions of sequences; using the variant tool FlashTAP, teams can filter out liability flags and predict therapeutic developability metrics for 100 antibodies per second.
    • Having said that, CDR-H3 is still sota - so in the region of 2.5A, but it gets there way faster.
    • Novel de novo protein binder design pipeline from Boltz that pairs an optimized candidate generation engine with BoltzPPI, a novel, interaction-aware scoring model built to rank designs based on binding confidence rather than just geometric plausibility.
    • To train BoltzPPI, the authors created a set of positive labels (PDB and patent complexes) and negative labels (synthetic non-interacting protein pairs co-localized via Boltz-2). This input pool (token, pair, distance, and mask features) is processed through a Pairformer stack using specific optimization tricks (co-trained focal loss, multi-view representation dropping, and Gaussian noise injection) to predict a binary binding-confidence score.
    • Significantly improves experimental VHH design performance, boosting the confirmed-binder hit rate from 3.3% to 8.0% on novel targets and successfully discovering screening hits for 7 out of 10 benchmark targets from the Chai-2 dataset.
    • Yields highly manufacturable binders, with 58% of its confirmed candidates passing a comprehensive panel of strict biophysical filters (such as thermal stability, purity, and low aggregation Propensity), outperforming both BoltzGen (40%) and clinical-stage VHH controls (21%).
    • Generates structurally distinct binders whose CDR loops remain highly distinct from any known entries in the SAbDab database, with the entire pipeline made available to researchers via the Boltz API and Lab platforms.
    • Case study of JAM-2, a generative biomolecular design model that engineered drug-like VHH antibodies against five distinct peptide-MHC class I (pMHC-I) targets across two HLA alleles using only target amino acid sequences as input.
    • When reformatted into bispecific T-cell engagers (TCEs) without experimental optimization, the designs mediated potent, sub-nanomolar T-cell activation and successfully directed primary human T cells to kill target-presenting cells.
    • Binders achieved stringent selectivity, showing a minimum 216-fold preference for NY-ESO-1 over highly similar human self-peptides and safely discriminating mutant KRAS variants (G12V and G12C) from wild-type sequences. A cryo-EM structure verified this atomic accuracy with a whole-complex Ca RMSD of 0.93 Å.
    • Bypassing the need for downstream engineering, 78% of the designed antibodies passed five core industry-standard biophysical developability criteria, exhibiting strong expression titers, favorable monomericity, thermal stability, and low polyreactivity
    • Theoretical framework for predicting molecular recognition from sequence alone structures are not required at inference time.
    • The selection probability governing which molecules bind which is provably unique, it is the Boltzmann distribution, derived from first principles rather than assumed.
    • To use it, we need sequence representations whose dot product approximates relative binding energies, not just higher for binders vs non-binders, but correctly ranking the full competitor pool.
    • This separates two problems: learning the embedding geometry (cheap, binary binding pairs) from recovering absolute binding energies (cheap, just two calibration parameters fitted against a small number of experimental KdK_d Kd​ measurements).
    • New language model addressing the germline bias in NGS training data.
    • GermRL fine-tunes an autoregressive ProGen2-OAS base model using a modified, outcome-supervised Group Relative Policy Optimization (GRPO) framework that features epoch-end weight syncing and automated "prefix grafting." So instead of using an absolute baseline, GRPO generates a local batch of sequences simultaneously; since the reward function favors mutations, any safely mutated sequence scores higher than its germline-heavy peers, resulting in a positive relative z-score that "up-votes" the mutated path while "down-voting" the underperforming germline ones.
    • This is the first framework to fix germline bias in generative, autoregressive models (unlike previous efforts that targeted masked models), and it acts as a lightweight, modular plugin requiring no scratch training or data pre-processing.
    • It was evaluated on one-shot generation success (pass@1) across specific mutation bounds (LD5 to LD35), measuring structural plausibility via ESMFold, sequence/V-gene diversity, developability metrics (GRAVY/instability), and semantic overlap with natural human antibodies using AntiBERTy UMAP embeddings.
    • Deep learning framework designed to predict both highly accurate single antibody structures and biologically realistic 3D conformational ensembles.
    • It combines a fast, antibody-specific sequence alignment tool (Abalign) with an optimized OpenFold engine, utilizing a novel "split-and-intersect" cross-chain clustering strategy to properly model heavy-light chain coordination without chain-segregation bias.
    • In static benchmarks, it outperforms top-tier models like AlphaFold3 and IgFold, especially on the notoriously difficult hypervariable CDR-H3 loop, while cutting down structure inference time to roughly 2 minutes per antibody.
    • Validated against extensive Molecular Dynamics (MD) simulations, its generated ensembles accurately capture true biological flexibility rather than random sampling noise, which significantly improves downstream therapeutic evaluations like antibody aggregation and developability mapping.
    • An end-to-end structural refinement method specifically developed for antibodies and nanobodies.
    • Curates structures from SAbDab to train a pure equivariant graph transformer (not a standard EGNN) that directly predicts 3D coordinate shift vectors for all backbone atoms (N, Ca, C, O).
    • Benchmarked against five baseline methods, achieving an average Ca RMSD improvement typically on the order of 0.01 Å to 0.05 Å - which essentially is raising questions of statistical significance (as the error bars are order of 1.0A at least).
    • Protein Language model that understands protein dynamics.
    • The authors leveraged existing structural data and datasets like mdCATH to gather equilibrium fluctuations for 64,403 proteins. Instead of raw time-series trajectories, they extracted calculated biophysical properties like root-mean-square fluctuations (RMSF) and Normal Mode Analysis (NMA) to serve as training labels.
    • They trained two models, SeqDance 'from scratch' and ESMDance as an extension of ESM2. ESMDance: Built by fine-tuning the pre-trained ESM-2 transformer, teaching it to map its existing evolutionary knowledge to these new physical flexibility profiles. SeqDance: Trained completely from scratch using only raw sequences and the target dynamics data, forcing it to learn pure, unbiased residue co-movement and physics.
    • To test zero-shot mutation prediction, the models compare the wild-type flexibility against the mutated sequence's flexibility. A large mathematical discrepancy flags a highly disruptive, damaging mutation. These predicted shifts were correlated against deep mutational scanning (DMS) lab data measuring actual cellular fitness and stability changes. ESMDance is the go-to for mutation prediction (especially on viral and de novo designed proteins with no evolutionary history), while SeqDance wins at modeling highly flexible Intrinsically Disordered Regions (IDRs).